» Articles » PMID: 31010051

Inhibition of IL-13 and IL-13Rα2 Expression by IL-32θ in Human Monocytic Cells Requires PKCδ and STAT3 Association

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Apr 24
PMID 31010051
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin (IL)-32θ, a newly identified IL-32 isoform, has been reported to exert pro-inflammatory effects through the association with protein kinase C delta (PKCδ). In this study, we further examined the effects of IL-32θ on IL-13 and IL-13Rα2 expression and the related mechanism in THP-1 cells. Upon stimulating IL-32θ-expressing and non-expressing cells with phorbol 12-myristate 13-acetate (PMA), the previous microarray analysis showed that IL-13Rα2 and IL-13 mRNA expression were significantly decreased by IL-32θ. The protein expression of these factors was also confirmed to be down-regulated. The nuclear translocation of transcription factors STAT3 and STAT6, which are necessary for IL-13Rα2 and IL-13 promoter activities, was suppressed by IL-32θ. Additionally, a direct association was found between IL-32θ, PKCδ, and signal transducer and activator of transcription 3 (STAT3), but not STAT6, revealing that IL-32θ might act mainly through STAT3 and indirectly affect STAT6. Moreover, the interaction of IL-32θ with STAT3 requires PKCδ, since blocking PKCδ activity eliminated the interaction and consequently limited the inhibitory effect of IL-32θ on STAT3 activity. Interfering with STAT3 or STAT6 binding by decoy oligodeoxynucleotides (ODNs) identified that IL-32θ had additive effects with the STAT3 decoy ODN to suppress IL-13 and IL-13Rα2 mRNA expression. Taken together, our data demonstrate the intracellular interaction of IL-32θ, PKCδ, and STAT3 to regulate IL-13 and IL-13Rα2 synthesis, supporting the role of IL-32θ as an inflammatory modulator.

Citing Articles

IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients.

Karamikheirabad M, Zhang J, Ahn A, Park H, Park S, Moon Y Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598436 PMC: 11597473. DOI: 10.3390/ph17111526.


Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.

Liang R, Wu C, Liu S, Zhao W Drug Deliv. 2022; 29(1):1620-1630.

PMID: 35612318 PMC: 9135425. DOI: 10.1080/10717544.2022.2075986.


A Critical Overview of Interleukin 32 in Leishmaniases.

Ribeiro-Dias F, Oliveira I Front Immunol. 2022; 13:849340.

PMID: 35309341 PMC: 8927017. DOI: 10.3389/fimmu.2022.849340.


Genetics and Functional Mechanisms of STAT3 Polymorphisms in Human Tuberculosis.

Wang F, Huang G, Shen L, Peng Y, Sha W, Chen Z Front Cell Infect Microbiol. 2021; 11:669394.

PMID: 34307193 PMC: 8294188. DOI: 10.3389/fcimb.2021.669394.


STAT3 and p53: Dual Target for Cancer Therapy.

Pham T, Park H, Kim J, Hong J, Yoon D Biomedicines. 2020; 8(12).

PMID: 33371351 PMC: 7767392. DOI: 10.3390/biomedicines8120637.


References
1.
Orchansky P, Kwan R, Lee F, Schrader J . Characterization of the cytoplasmic domain of interleukin-13 receptor-alpha. J Biol Chem. 1999; 274(30):20818-25. DOI: 10.1074/jbc.274.30.20818. View

2.
Jain N, Zhang T, Kee W, Li W, Cao X . Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. J Biol Chem. 1999; 274(34):24392-400. DOI: 10.1074/jbc.274.34.24392. View

3.
Bromberg J, Wrzeszczynska M, Devgan G, Zhao Y, Pestell R, Albanese C . Stat3 as an oncogene. Cell. 1999; 98(3):295-303. DOI: 10.1016/s0092-8674(00)81959-5. View

4.
Kontny E, Kurowska M, Szczepanska K, Maslinski W . Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. J Leukoc Biol. 2000; 67(2):249-58. DOI: 10.1002/jlb.67.2.249. View

5.
Akira S . Roles of STAT3 defined by tissue-specific gene targeting. Oncogene. 2000; 19(21):2607-11. DOI: 10.1038/sj.onc.1203478. View